Literature DB >> 17138067

P300 and treatment effect of modafinil on fatigue in multiple sclerosis.

G Nagels1, M B D'hooghe, L Vleugels, D Kos, M Despontin, P P De Deyn.   

Abstract

To evaluate the value of visual and auditory P300 for predicting the response of multiple sclerosis-related fatigue to modafinil treatment, 33 patients were treated with 100 mg modafinil once daily for 4 weeks, following a 4-week baseline phase and an optional 8-week extension phase. The main clinical outcome parameter was a decrease in the fatigue visual analogue score (VAS) before and after 4 weeks of treatment. Patients with shorter auditory P300 latency at baseline were more likely to benefit from modafinil treatment. Auditory P300 latency predicted treatment response with a specificity of 76% and a sensitivity of 75% at a cut-off latency of 350 ms. Visual P300 latency could not be used to predict treatment response. Baseline auditory P300 latency predicted treatment response, whereas visual P300 latency did not. Clinical improvement did not correlate with changes in either visual or auditory P300.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17138067     DOI: 10.1016/j.jocn.2005.10.008

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  8 in total

Review 1.  Neurophysiological correlates of cognitive disturbances in multiple sclerosis.

Authors:  Letizia Leocani; Javier J Gonzalez-Rosa; Giancarlo Comi
Journal:  Neurol Sci       Date:  2010-11       Impact factor: 3.307

2.  Daytime sleepiness in elderly Parkinson's disease patients and treatment with the psychostimulant modafinil: A preliminary study.

Authors:  Johan Lökk
Journal:  Neuropsychiatr Dis Treat       Date:  2010-04-07       Impact factor: 2.570

3.  Modafinil effects on middle-frequency oscillatory power during rule selection in schizophrenia.

Authors:  Michael J Minzenberg; Jong H Yoon; Yaoan Cheng; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2014-06-26       Impact factor: 7.853

Review 4.  Fatigue as a symptom or comorbidity of neurological diseases.

Authors:  Iris-Katharina Penner; Friedemann Paul
Journal:  Nat Rev Neurol       Date:  2017-10-13       Impact factor: 42.937

5.  Event-related potentials and cognitive performance in multiple sclerosis patients with fatigue.

Authors:  Anna Pokryszko-Dragan; Mieszko Zagrajek; Krzysztof Slotwinski; Malgorzata Bilinska; Ewa Gruszka; Ryszard Podemski
Journal:  Neurol Sci       Date:  2016-06-06       Impact factor: 3.307

6.  Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure.

Authors:  Roman Zenouzi; Janina von der Gablentz; Marcus Heldmann; Martin Göttlich; Christina Weiler-Normann; Marcial Sebode; Hanno Ehlken; Johannes Hartl; Anja Fellbrich; Susanne Siemonsen; Christoph Schramm; Thomas F Münte; Ansgar W Lohse
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

Review 7.  The Potential Role of Neurophysiology in the Management of Multiple Sclerosis-Related Fatigue.

Authors:  Fioravante Capone; Francesco Motolese; Emma Falato; Mariagrazia Rossi; Vincenzo Di Lazzaro
Journal:  Front Neurol       Date:  2020-04-22       Impact factor: 4.003

Review 8.  Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis.

Authors:  Zina-Mary Manjaly; Neil A Harrison; Hugo D Critchley; Cao Tri Do; Gabor Stefanics; Nicole Wenderoth; Andreas Lutterotti; Alfred Müller; Klaas Enno Stephan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-01-25       Impact factor: 10.154

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.